Bioventus Inc. (BVS): Price and Financial Metrics

Bioventus Inc. (BVS): $2.45

0.26 (+11.87%)

POWR Rating

Component Grades














  • BVS scores best on the Value dimension, with a Value rank ahead of 90.15% of US stocks.
  • The strongest trend for BVS is in Momentum, which has been heading up over the past 179 days.
  • BVS ranks lowest in Sentiment; there it ranks in the 11th percentile.

BVS Stock Summary

  • BVS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.52 -- higher than only 4.68% of US-listed equities with positive expected earnings growth.
  • BVS's went public 1.76 years ago, making it older than merely 7.14% of listed US stocks we're tracking.
  • BIOVENTUS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -76.71%, greater than the shareholder yield of merely 6.86% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BIOVENTUS INC are TREE, VEEE, TMCI, INGN, and TCMD.
  • To check out BIOVENTUS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001665988.

BVS Valuation Summary

  • In comparison to the median Healthcare stock, BVS's price/earnings ratio is 232.89% lower, now standing at -29.7.
  • Over the past 21 months, BVS's price/earnings ratio has gone up 1551.2.

Below are key valuation metrics over time for BVS.

Stock Date P/S P/B P/E EV/EBIT
BVS 2022-11-01 1.2 1.3 -29.7 -38.4
BVS 2022-10-31 1.3 1.4 -31.6 -39.9
BVS 2022-10-28 1.2 1.4 -30.7 -39.2
BVS 2022-10-27 1.2 1.3 -29.1 -37.9
BVS 2022-10-26 1.2 1.3 -28.8 -37.6
BVS 2022-10-25 1.1 1.2 -27.8 -36.8

BVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BVS has a Quality Grade of B, ranking ahead of 80.64% of graded US stocks.
  • BVS's asset turnover comes in at 0.664 -- ranking 57th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows BVS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.664 0.727 0.113

BVS Stock Price Chart Interactive Chart >

Price chart for BVS

BVS Price/Volume Stats

Current price $2.45 52-week high $15.57
Prev. close $2.19 52-week low $1.65
Day low $2.18 Volume 405,400
Day high $2.50 Avg. volume 250,812
50-day MA $5.90 Dividend yield N/A
200-day MA $9.05 Market Cap 189.75M

Bioventus Inc. (BVS) Company Bio

Bioventus Inc. focuses on operating as a holding company for Bioventus LLC that operates as a medical device company. It develops and commercializes clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is based in Durham, North Carolina.

BVS Latest News Stream

Event/Time News Detail
Loading, please wait...

BVS Latest Social Stream

Loading social stream, please wait...

View Full BVS Social Stream

Latest BVS News From Around the Web

Below are the latest news stories about BIOVENTUS INC that investors may wish to consider to help them evaluate BVS as an investment opportunity.

Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance

DURHAM, N.C., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022. Due to the adverse effect on the previously announced third quarter 2022 financial results and revenue guidance that resulted from additional rebate claims related to certain of the Company’s products and a non-cash impairment cha

Yahoo | November 21, 2022

Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022

DURHAM, N.C., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company has filed a Form 12b-25, Notification of Late Filing for its Quarterly Report on Form 10-Q for the period ended October 1, 2022. As a result of the recent decline in the Company’s market capitalization subsequent to its previously announced financial results for the third quarter of 2022 ("Q3 Earnings Release")

Yahoo | November 16, 2022

Bioventus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Bioventus ( NASDAQ:BVS ) Third Quarter 2022 Results Key Financial Results Revenue: US$137.1m (up 26% from 3Q 2021). Net...

Yahoo | November 10, 2022

Why Shares of Bioventus Fell 14% on Wednesday

Shares of Bioventus (NASDAQ: BVS) fell 14% on Wednesday. The medical device company's stock closed on Tuesday at $3 a share, then opened on Wednesday at $2.90. Bioventus focuses on making treatments that enhance the body's natural healing process, such as ultrasound bone healing systems and bone graft materials.

Yahoo | November 9, 2022

Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance

DURHAM, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights: Net Sales of $137.1 million, up $28.2 million, or 25.9%, year-over-year as reported (26.8% constant currency*) and 7.3% organically* (8.1% constant currency*)Net Income of $3.2 million, compared to Net Loss of $2

Yahoo | November 8, 2022

Read More 'BVS' Stories Here

BVS Price Returns

1-mo -67.33%
3-mo -68.39%
6-mo N/A
1-year -80.42%
3-year N/A
5-year N/A
YTD -83.09%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7848 seconds.